Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05307237 · ClinicalTrials.gov registry record · NA

Continuous Glucose Monitoring for High-Risk Type 2 Diabetes in the Hospital (Cyber GEMS)

A NA study, sponsored by Scripps Whittier Diabetes Institute.

Completed
Registry status
NA
Development phase
518
Enrollment target

NCT05307237 is a NA study that has completed, run by Scripps Whittier Diabetes Institute. The registered enrollment target is 518 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05307237, a NA study, has completed, sponsored by Scripps Whittier Diabetes Institute.

COMPLETED
Registry status
NA
Development phase
518 participants
Enrollment target

Study Summary

Given the known serious consequences of uncontrolled blood sugars during hospitalization, this research plans to study an alternative seamlessly integrated continuous glucose monitoring (CGM) system in the hospital to test a dynamic and digitized, team-based approach to glucose management in an underserved and understudied, yet high-risk population. A digital dashboard will facilitate real-time, remote monitoring of a large volume of patients simultaneously; automatically identify and prioritize patients for intervention; and will detect any and all potentially dangerous hypoglycemic episodes in a hospital environment. The study will focus on clinical metrics of glucose control and infection that are in-line with patient priorities and US hospital quality initiatives.

Interventions

  • DEVICE Dexcom G6 Continous Glucose Monitoring Management
  • DEVICE Usual Care - Blinded Continuous Glucose Monitoring Management

Trial Details

FieldValue
Enrollment Target 518 participants
Start Date 2022-04-19
Est. Completion 2025-12-17
Phase NA

What the Registry Record Tells You About NCT05307237

The ClinicalTrials.gov registry entry for NCT05307237 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 518 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scripps Whittier Diabetes Institute, which has 17 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Dexcom G6 Continous Glucose Monitoring Management is the first listed.

NCT05307237 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05307237 about?

NCT05307237 is a clinical study titled "Continuous Glucose Monitoring for High-Risk Type 2 Diabetes in the Hospital (Cyber GEMS)". Given the known serious consequences of uncontrolled blood sugars during hospitalization, this research plans to study an alternative seamlessly integrated continuous glucose monitoring (CGM) system in the hospital to test a dynamic and digitized, team-based approach to glucose management in an unde...

What is the current status of trial NCT05307237?

This trial is currently completed. It is a NA study. The enrollment target is 518 participants. The study started on 2022-04-19. Estimated completion is 2025-12-17.

What interventions are being tested in trial NCT05307237?

The interventions under investigation include: Dexcom G6 Continous Glucose Monitoring Management (DEVICE), Usual Care - Blinded Continuous Glucose Monitoring Management (DEVICE).

Who is sponsoring clinical trial NCT05307237?

This trial is sponsored by Scripps Whittier Diabetes Institute, which has 17 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.